Wednesday, July 28, 2021

Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product

Diabetes cure: USFDA approves Biocon#39;s long-acting insulin Semglee as first interchangeable biosimilar product Diabetes cure: USFDA’s designation of Semglee (insulin glargine) as interchangeable with Lantus (insulin glargine of Sanofi) means that Semglee may now be substituted for the reference product at the pharmacy without the intervention of the prescriber.

from Moneycontrol Business News https://ift.tt/3f9mtIh
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

S&P 500, Nasdaq end higher on Amazon-OpenAI deal; Fed path forward grows murky

Artificial intelligence deals propelled the S&P 500 and Nasdaq higher on Monday, with Amazon's $38 billion agreement with OpenAI and...